BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
Insilicom, LLC, founded in 2012 by Dr. Jinfeng Zhang in Florida, is dedicated to unleashing the power of big data to accelerate scientific discovery through innovative computational approaches. With a mission to become an industry leader in AI-powered big data analytics and mining for the biomedical field, Insilicom develops cutting-edge platforms that integrate advanced machine learning, natural language processing, and large-scale knowledge graphs. The company has won multiple international challenges in biomedical AI and NLP, including the LitCoin NLP Challenge organized by NIH and NASA (2022), the BioCreative Challenge VIII Knowledge Graph track (2023), and the BioASQ Task 13B semantic question answering competition (2025). Current flagship products include IKraph, a high-quality biomedical knowledge graph, and IDEAL (Insilicom Data Exploration and Learning), a powerful framework for drug discovery, target validation, and data harmonization. Insilicom is also preparing to launch IKnow, a fact-checking tool for biomedical knowledge, by the end of 2025.
Dedicated to transplant patients. Leading with innovation. Personalized care for every step of the transplant journey.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
The Biopharmaceutical (BIOP) Section of the American Statistical Association (ASA) was established in 1968 as a subsection of the Biometrics Section. Following rapid membership growth, it became a full section of the ASA in 1981. Today, BIOP is one of the most active ASA sections, focusing on the application of statistics to the development and use of therapeutic drugs and devices in both humans and animals.
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong pipeline. To learn more, please visit www.biomarin.com.
Astellas Phama U.S., Inc., is an affiliate of Astellas Pharma Inc., a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women’s health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 30 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 19,000 + employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on us.
We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Sentieon®, incorporated in July 2014, develops highly-optimized algorithms for bioinformatics applications, using the team’s expertise in algorithm, software, and system optimization.
Sentieon® is a team of professionals experienced in image processing, telecom, computational lithography, large-scale data mining, and bioinformatics. Using our accumulated expertise in modeling, optimization, machine learning, and high-performance computing, we strive to enable precision data for precision medicine.
Biostatistics Symposium of Southern California (BSSC) is a non-profit organization with a 501(c)(3) tax-exempt status. Our committee members come from diverse backgrounds within the pharmaceutical and academia communities, much like those who attend our event. In fact, many of us began as attendees ourselves before stepping into committee roles. This unique perspective allows us to create an event that speaks directly to the needs and interests of biostatisticians, data scientists, and industry professionals alike. We are passionate about fostering collaboration, advancing knowledge, and supporting the growth of the life sciences field.
DahShu 2025 ContactFor all general questions about the symposium, including program details, registration, and logistics: Email: dahshu2025@gmail.com | Our Social Networks |